Infectious disease AI scribe 2026: antibiotic stewardship, OPAT, HIV / HCV, travel consult, and the long-form ID note workflow

May 9, 2026 · 6 min read

Infectious disease produces some of the longest narrative consults in medicine. A complex bone-and-joint infection or endocarditis case can yield a four-page consult note covering exposure history, microbiology synthesis across multiple cultures and timepoints, antibiotic timeline reconciliation, source-control assessment, and a multi-week treatment plan with audit hooks for stewardship. ID is also one of the most-audited specialties: antibiotic stewardship programs scrutinize every broad-spectrum order, and OPAT (Outpatient Parenteral Antibiotic Therapy) carries its own documentation chain across the lab, pharmacy, infusion vendor, and home health agency.

The 2026 ID-aware AI scribe stack handles five things: long-form consult note structure that ID actually uses (history, exam, micro synthesis, A/P by problem), stewardship audit fields, OPAT order substantiation, HIV / HCV cure-program documentation, and the travel medicine consult schema for pre-travel and post-travel encounters.

Visit-type adaptation

ID has six core visit types:

• Inpatient consult — long-form, source / pathogen / treatment focus, recommendations to primary team.
• OPAT planning and follow-up — vascular access, weekly labs, infusion safety, transition to oral.
• HIV care continuum — ART regimen, viral load, CD4, co-infection (HBV, HCV, syphilis, opportunistic), prevention.
• HCV cure program — DAA selection by genotype, baseline labs, on-treatment monitoring, SVR-12 confirmation.
• Travel medicine — itinerary risk assessment, vaccinations, prophylaxis (malaria, traveler's diarrhea, altitude).
• Outpatient general ID — bone / joint, complicated UTI, recurrent cellulitis, post-discharge endocarditis.

The scribe should detect visit type from context and apply the appropriate schema.

The ID system prompt

You are documenting an infectious disease encounter or consult.

INPUT:
- Encounter audio transcript or chart review notes
- Patient profile: comorbidities, immunosuppression status, allergies (esp.
  abx), prior MDRO history, recent hospitalizations, travel/exposure history
- Microbiology data: cultures by site / date / organism / susceptibilities
- Antibiotic timeline (start/stop/dose/route)
- Imaging results
- For HIV: ART history, viral load / CD4 trajectory
- For HCV: genotype, fibrosis stage, prior DAA exposure
- For OPAT: vascular access type, infusion vendor, home health agency

DETERMINE visit type, then apply schema:

For inpatient consult:
1. Reason for consult and clinical question
2. HPI by problem with relevant exposure history
3. Pertinent PMH / immunosuppression / abx allergy
4. ROS focused
5. Exam (inspection of any infected site, vital signs, source-relevant findings)
6. Microbiology synthesis (each culture: site, date, organism, suscept) with
   chronological timeline of antibiotic decisions
7. Imaging synthesis
8. Differential and Assessment / Plan by problem
9. Antibiotic recommendations: drug, dose, route, planned duration with stop
   date, level monitoring if applicable (vanco, gent, beta-lactam TDM)
10. Source control assessment (drainage, hardware removal, debridement)
11. Stewardship-aligned narrowing or de-escalation rationale
12. Follow-up plan including OPAT transition criteria if applicable

For OPAT planning:
1. Diagnosis and indication for IV antibiotics
2. Antibiotic, dose, frequency, planned duration
3. Vascular access type (PICC, midline, port, tunneled)
4. Weekly lab plan (CBC, BMP, drug levels, drug-specific safety labs)
5. Infusion vendor, home health agency, supervising clinician
6. Patient / caregiver teaching documented
7. Transition-to-oral criteria if applicable
8. Stewardship review

For HIV care continuum:
1. ART regimen with adherence assessment
2. Viral load and CD4 trajectory
3. Co-infection status (HBV, HCV, syphilis, TB)
4. Opportunistic infection prophylaxis appropriate to CD4
5. Vaccination status
6. Mental health and substance use screening
7. Cardiometabolic / bone / renal monitoring per regimen
8. PrEP / PEP discussion if relevant
9. Plan: regimen continue / switch with reasoning, lab plan, follow-up

For HCV cure:
1. Genotype, baseline VL, fibrosis stage
2. DAA regimen selected with rationale (genotype-specific, GT1a RAS check
   if relevant)
3. Drug interaction screen
4. Baseline labs (LFTs, renal, HBV)
5. On-treatment lab monitoring (Week 4 RNA)
6. End-of-treatment and SVR-12 plan
7. Reinfection risk counseling

For travel medicine:
1. Itinerary (countries, dates, activities, accommodation)
2. Patient profile (age, pregnancy, immunosuppression, allergies)
3. Required and recommended vaccinations
4. Malaria prophylaxis selection by destination + drug-interaction check
5. Traveler's diarrhea, altitude, mosquito-avoidance counseling
6. Documentation for visa / yellow-fever requirements

STEWARDSHIP AUDIT FIELDS (for any broad-spectrum or restricted abx):
- Indication
- Cultures sent before initiation if possible
- Allergy reconciliation
- Renal/hepatic dose adjustment confirmed
- De-escalation criteria stated
- Planned duration with stop date

Cite transcript and labs. Use IDSA-aligned terminology.

Antibiotic stewardship as the audit driver

Antibiotic stewardship programs review broad-spectrum orders for indication, duration, and de-escalation. ID consult notes that do not surface stewardship fields explicitly (indication, planned stop date, narrowing rationale, level monitoring) get bounced back. A scribe with stewardship-aware fields produces consult notes that close those loops at the source.

OPAT documentation chain

Outpatient Parenteral Antibiotic Therapy crosses pharmacy, infusion vendor, home health, and lab. Documentation must support each handoff: vascular access plan, weekly lab schedule, drug-level monitoring, transition-to-oral criteria. ID-tuned scribes produce the OPAT plan in a structure the home health agency and infusion vendor can act on without callbacks.

HIV / HCV cure programs

HIV care has standardized maintenance documentation (regimen, viral load, CD4, co-infection, prophylaxis, vaccinations, lab monitoring) that maps cleanly to a templated schema. HCV cure programs are time-limited and document-heavy: genotype, fibrosis stage, DAA selection rationale, drug interactions, on-treatment monitoring, SVR-12 confirmation. A scribe with both schemas produces the longitudinal documentation that program funders (Ryan White, state DPH, commercial HCV cure programs) audit.

The ID volume economics

An outpatient ID physician seeing 12-18 patients per day across HIV continuum, HCV cure, OPAT follow-up, and outpatient consults averages 30-45 min per visit. Per-day audio: ~10-12 hours × $0.05 = ~$30-36/day with the LessRec DIY stack. Inpatient consult ID can be even more variable (weekend coverage, on-call surges). Variable cost beats subscription floor for this profile.

Vendor and DIY paths

Vendor scribes capture conversation. They underdeliver on long-form consult structure, microbiology timeline synthesis, stewardship audit fields, OPAT chain documentation, and HIV / HCV program-aware schemas. The DIY stack — LessRec Whisper API + an ID-tuned prompt + your EHR's consult template — produces consults that read like ID consults.

BAA chain

Practice + EHR + microbiology lab feed + (for OPAT) infusion vendor + home health + (for HIV / HCV) program reporting platforms (CAREWare, etc.) + transcription vendor + LLM vendor.

When to start

ID practices with substantial OPAT, HIV continuum, or HCV cure volume have the strongest case for a long-form-aware DIY stack. The consult note IS the product; structured documentation that satisfies stewardship, payors, and program funders is the audit-defensible default.